Clinical Trials Arena on MSN
Takeda’s platelet disorder drug triggers up to 91% response rate
The Japanese pharma is currently investigating mezagitamab’s potential in two late-stage autoimmune programmes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results